Tumor growth curves indicated that mice subcutaneously primed and intratumorally boosted with HER2-expressing virus (VG22401) had better antitumor efficacy compared to mice treated with the vehicle and non-HER2-expressing virus (VG2062). Here, ERBB2 is linked to neoplasm.